دورية أكاديمية
أعرض في EDS

Inhibition of urinary bladder cancer cell proliferation by silibinin.

التفاصيل البيبلوغرافية
العنوان: Inhibition of urinary bladder cancer cell proliferation by silibinin.
المؤلفون: Barros TMB; Programa de Pós-graduação em Ciências Farmacêuticas (CIPHARMA), Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais, Brazil., Lima APB; Programa de Pós-graduação em Ciências Farmacêuticas (CIPHARMA), Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais, Brazil., Almeida TC; Programa de Pós-graduação em Ciências Farmacêuticas (CIPHARMA), Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais, Brazil., da Silva GN; Programa de Pós-graduação em Ciências Farmacêuticas (CIPHARMA), Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais, Brazil.; Departamento de Análises Clínicas (DEACL), Escola de Farmácia, Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais, Brazil.; Programa de Pós-graduação em Ciência Biológicas (CBIOL), Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais, Brazil.
المصدر: Environmental and molecular mutagenesis [Environ Mol Mutagen] 2020 Apr; Vol. 61 (4), pp. 445-455. Date of Electronic Publication: 2020 Mar 03.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 8800109 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1098-2280 (Electronic) Linking ISSN: 08936692 NLM ISO Abbreviation: Environ Mol Mutagen Subsets: MEDLINE
أسماء مطبوعة: Publication: New York Ny : Wiley-Liss
Original Publication: New York, NY : Liss, c1987-
مواضيع طبية MeSH: Antineoplastic Agents, Phytogenic/*pharmacology , Cell Proliferation/*drug effects , Silybin/*pharmacology , Urinary Bladder Neoplasms/*drug therapy, Apoptosis/drug effects ; Cell Cycle/drug effects ; Cell Line, Tumor ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Tumor Suppressor Protein p53/genetics ; Urinary Bladder Neoplasms/genetics ; Urinary Bladder Neoplasms/pathology
مستخلص: Silibinin, a natural compound extracted from milk thistle, has demonstrated antitumor properties in urinary bladder cancer cells; however, the role of TP53 gene in these effects is unclear. In order to better understand the molecular and antiproliferative mechanisms of this compound, urinary bladder cancer cells with different TP53 gene status, RT4 (low-grade tumor, wild TP53 gene), 5637 (high-grade tumor, Grade 2, mutated TP53 gene), and T24 (high-grade tumor, Grade 3, mutated TP53 gene) were treated with several concentrations of silibinin (1, 5, 10, 50, 100, and 150 μM). Cytotoxicity, prooxidant effect, morphological changes, cell migration, cell cycle progression, global methylation profile, and relative expression of HOXB3, c-MYC, PLK1, SMAD4, SRC, HAT, HDAC, and RASSF1A genes were evaluated. The silibinin presented cytotoxic and prooxidant effects in the three cell lines. In mutated TP53 cells, significant interference in cell migration and cell cycle arrest at the G2/M phase was observed. Additionally, silibinin induced global DNA hypomethylation in the highest grade tumor cells. For wild-type TP53 cells, a sub-G1 apoptotic population was present. Furthermore, there was modulation of gene expression responsible for cell growth (SMAD and c-MYC), migration (SRC), cell cycle kinetics (PLK1), angiogenesis (HOXB3), and of genes associated with epigenetic events such as DNA acetylation (HAT) and deacetylation (HDAC). In conclusion, the silibinin inhibited the urinary bladder tumor cell proliferation independently of TP53 status; however, cell cycle effects, gene expression changes, and alteration of cell migration are dependent on TP53 status. © 2020 Wiley Periodicals, Inc.
(© 2020 Wiley Periodicals, Inc.)
References: Adjei, B.E., Buchanan, P., Hinyard, L., Osazuwa-peters, N., Simpson, M.C., Schootman, M. and Piccirillo, J.F. (2019) Trends in the risk and burden of second primary malignancy among survivors of smoking-related cancers in the United States. International Journal of Cancer, 1, 1-11.
Aljabery, F., Shabo, I., Gimm, O., Jahnson, S. and Olsson, H. (2018) The expression profile of p14, p53 and p21 in tumour cells is associated with disease-specific survival and the outcome of postoperative chemotherapy treatment in muscle-invasive bladder cancer. Urologic Oncology, 36, 1-12.
Arango, D., Corner, G.A., Wadler, S., Catalano, P.J. and Augenlicht, L.H. (2001) C-myc/p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo. Cancer Research, 61, 4910-4915.
Bhatlekar, S., Fields, J.Z. and Bruce, M. (2018) Role of HOX genes in stem cell differentiation and cancer. Stem Cells International, 2018, 1-15.
Brassesco, M.S., Pezuk, J.A., Morales, A.G., de Oliveira, J.C., Roberto, G.M., da Silva, G.N., Francisco de Oliveira, H., Scrideli, C.A. and Tone, L.G. (2013) In vitro targeting of polo-like kinase 1 in bladder carcinoma: comparative effects of four potent inhibitors. Cancer Biology & Therapy, 14, 648-657.
Camargo, E.A., Da Silva, G.N., Gobette, C.P., Marcondes, J.P. and Salvadori, D.M. (2013) No relationship between the amount of DNA damage and the level of hMLH1 and RASSF1A gene expression in bladder cancer cells treated with cisplatin and gemcitabine. Asian Pacific Journal of Cancer Prevention, 14, 5941-5948.
Carioli, G., Bertuccio, P., Malvezzi, M., Rodriguez, T., Levi, F., Boffetta, P., La Vecchia, C. and Negri, E. (2019) Cancer mortality predictions for 2019 in Latin America. International Journal of Cancer, 2019, 1-27.
Chikara, S., Lindsey, K., Borowicz, P., Christofidou-Solomidou, M. and Reindl, K.M. (2017) Enterolactone alters FAK-Src signaling and suppresses migration and invasion of lung cancer cell lines. BMC complement. Alternative Medicine, 17, 1-12.
Compérat, E., Varinot, J., Moroch, J., Eymerit-Morin, C. and Brimo, F.A. (2018) Practical guide to bladder cancer pathology. Nature. Revista de Urología, 15, 143-154.
Cooper, M.J., Haluschak, J.J., Johsond, D., Schwartz, S., Morrison, L.J., Lippa, M., Hatzivassiliou, G. and Tan, J. (1994) p53 mutations in bladder carcinoma cell lines. Oncology Research, 6, 569-579.
Cordon-Cardo, C., Dalbagni, G., Saez, G.T., Oliva, M.R., Zhang, Z.F., Rosai, J., Reuter, V.E. and Pellicer, A. (1994) p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. International Journal of Cancer, 56, 347-353.
Da Silva, G.N., Camargo, E.A. and Salvadori, D.M.F. (2012) Toxicogenomic activity of gemcitabine in two TP53-mutated bladder cancer cell lines: special focus on cell cycle-related genes. Molecular Biology Reports, 39, 10373-10382.
Da Silva, G.N., De Castro, M.J.P., De Camargo, E.A., Da Silva, P.J.G.A., Sakamoto-Hojo, E.T. and Salvadori, D.M. (2010) Cell cycle arrest and apoptosis in TP53 subtypes of bladder carcinoma cell lines treated with cisplatin and gemcitabine. Experimental Biology and Medicine (Maywood, N.J.), 235, 814-824.
De Oliveira, D.T., Sávio, A.L.V., Marcondes, J.P.C., Barros, T.M., Barbosa, L.C., Salvadori, D.M.F. and Da Silva, G.N. (2017) Cytotoxic and toxicogenomic effects of silibinin in bladder câncer cells with different TP53 status. Journal of Biosciences, 42, 91-101.
Du, L., Xie, Z., Wu, L.C., Chiu, M., Lin, J., Chan, K.K., Liu, S. and Liu, Z. (2012) Reactivation of RASSF1A in breast cancer cells by curcumin. Nutrition and Cancer, 64, 1228-1235.
Duex, J.E., Swain, K.E., Dancik, G.M., Paucek, R.D., Owens, C., Churchill, M.E.A. and Theodorescu, D. (2018) Functional impact of chromatin remodeling gene mutations and predictive signature for therapeutic response in bladder cancer. Molecular Cancer Research, 16, 69-77.
Elston, R. and Inman, G.J. (2012) Crosstalk between p53 and TGF-β signalling. Journal of Signal Transduction, 2012, 1-10.
Fan, S., Yu, Y., Qi, M., Sun, Z., Li, L., Yao, G., Tashiro, S., Onodera, S. and Ikejima, T. (2012) P53-mediated GSH depletion enhanced the cytotoxicity of NO in silibinin-treated human cervical carcinoma HeLa cells. Free Radical Research, 46, 1082-1092.
Ferlay, J., Colombet, M., Soerjomataram, I., Mathers, C., Parkin, D.M., Piñeros, M., Znaor, A. and Bray, F. (2019) Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. International Journal of Cancer, 2019, 1-15.
Gándara, L., Sandes, E., Di Venosa, G.B., Prack Mc Cormick, P.M., Rodriguez, L., Mamon, A., Batlle, A.M. and Eiján, A.C. (2014) The natural flavonoid silybin improves the response to photodynamic therapy of bladder cancer cells. Journal of Photochemistry and Photobiology. B, Biology, 133, 55-64.
Gray, S., Pandha, H.S., Michael, A., Middleton, G. and Morgan, R. (2011) HOX genes in pancreatic development and cancer. Journal of the Pancreas, 12, 216-219.
Hirsch, C.L., Smith-Windsor, E.L. and Bonham, K. (2006) Src family kinase members have a common response to histone deacetylase inhibitors in human colon cancer cells. International Journal of Cancer, 118, 547-554.
Hulkower, K.I. and Herber, R.L. (2011) Cell migration and invasion assays as tools for drug discovery. Pharmaceutics, 3, 107-124.
Imai-Sumida, M., Chiyomaru, T., Majid, S., Saini, S., Nip, H., Dahiya, R., Tanaka, Y. and Yamamura, S. (2017) Silibinin suppresses bladder cancer through down-regulation of actin cytoskeleton and PI3K/Akt signaling pathways. Oncotarget, 54, 92032-92042.
Kastenhuber, E.R. and Lowe, S.W. (2017) Putting p53 in context. Cell, 170, 1062-1078.
Kazanets A, Shorstova T, Marques KM, Witcher M. (2016) Epigenetic silencing of tumor suppressor genes: paradigms, puzzles, and potential. Biochimica et Biophysica Acta 1865:275-288.
Kim, E., Giese, A. and Deppert, W. (2009) Wild type p53 in cancer cells: when a guardian turns into a blackguard. Biochemical Pharmacology, 77, 11-20.
Kim, W.T., Seo, S.P., Byun, Y.J., Kang, H.W., Kim, Y.J., Lee, S.C., Jeong, P., Song, H.J., Choe, S.Y., Kim, D.J., Kim, S.K., Há, Y.S., Moon, S.K., Lee, G.T., Kim, I.Y., Yun, S.J. and Kim, W.J. (2018) The anticancer effects of garlic extracts on bladder cancer compared to cisplatin: a common mechanism of action via centromere protein M. The American Journal of Chinese Medicine, 46, 689-705.
Lin, X., Wu, G., Huo, W.Q., Zhang, Y. and Jin, F.S. (2012) Resveratrol induces apoptosis associated with mitochondrial dysfunction in bladder carcinoma cells. International Journal of Urology, 19, 757-764.
Livak, K.J. and Schmittgen, T.D. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCt method. Methods, 25, 402-408.
Matsuo, T., Miyata, Y., Asai, A., Sagara, Y., Furusato, B., Fukuoka, J. and Hideki, S.H. (2017) Green tea polyphenol induces changes in cancer-related factors in an animal model of bladder cancer. PLoS One, 12, 1-13.
Mitsuho, I.S., Chiyomaru, T., Majid, S., Saini, S., Nip, H., Dahiya, R., Tanaka, Y. and Yamamura, S. (2017) Silibinin suppresses bladder cancer through down-regulation of actin cytoskeleton and PI3K/Akt signaling pathways. Oncotarget, 8, 92032-92042.
Peng, C.C., Chen, K.C., Peng, R.Y., Su, C.H. and Hsieh-Li, H.M. (2006) Human urinary bladder cancer T24 cells are susceptible to the Antrodia camphorata extracts. Cancer Letters, 243, 109-119.
Qiu, W., Lin, J., Zhu, Y., Zhang, J., Zeng, L., Su, M. and Tian, Y. (2017) Kaempferol modulates DNA methylation and downregulates DNMT3B in bladder cancer. Cellular Physiology and Biochemistry, 41, 1325-1335.
Reis, D. and Jones, T. (2017) Aromatherapy: using essential oils as a supportive therapy. Clinical Journal of Oncology Nursing, 21, 16-19.
Rieger, K.M., Little, A.F., Swart, J.M., Kastrinakis, W.V., Fitzgerald, J.M., Hess, D.T., Libertino, J.A. and Summerhayes, I.C. (1995) Human bladder carcinoma cell lines as indicators of oncogenic change relevant to urothelial neoplastic progression. British Journal of Cancer, 72, 683-690.
Sanli, O., Dobruch, J., Knowles, M.A., Burger, M., Alemozaffar, M., Nielsen, M.E. and Lotan, Y. (2017) Bladder cancer. Nature Reviews Disease Primers, 3, 1-19.
Savio, A.L., Da Silva, G.N. and Salvadori, D.M. (2015) Inhibition of bladder cancer cell proliferation by allyl isothiocyanate (mustard essential oil). Mutation Research, 771, 29-35.
Sharma, S., Kelly, T.K. and Jones, P.A. (2010) Epigenetics in cancer. Carcinogenesis, 31, 27-36.
Siegel, R.L., Miller, K.D. and Jemal, A. (2017) Cancer statistics, 2017. CA: A Cancer Journal of Clinicians, 67, 7-30.
Siegel, R.L., Miller, K.D. and Jemal, A. (2020) Cancer statistics, 2020. CA: Cancer Journal for Clinicians, 70, 7-30.
Strebhardt, K. (2010) Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nature Reviews Drug Discovery, 9, 643-660.
Tilley, S.K., William, K.Y. and Fry, R.C. (2017) Analysis of bladder cancer tumor CpG methylation and gene expression within the cancer genome atlas identifies GRIA1 as a prognostic biomarker for basal-like bladder cancer. American Journal of Cancer Research, 9, 1850-1862.
Tyagi, A., Agarwal, C., Harrison, G.L., Glode, M. and Agarwal, R. (2004) Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages. Carcinogenesis, 25, 1711-1720.
Tyagi, A., Raina, K., Singh, R.P., Gu, M., Agarwal, C., Harrison, G., Glode, L.M. and Agarwal, R. (2007) Chemopreventive effects of silymarin and silibinin on N-butyl-N-(4-hydroxybutyl) nitrosamine induced urinary bladder carcinogenesis in male ICR mice. Molecular Cancer Therapeutics, 6, 3248-3255.
Wapenaar, H. and Dekker, F.J. (2016) Histone acetyltransferases: challenges in targeting bisubstrate enzymes. Clinical Epigenetics, 8, 1-11.
Xu, L.X., Li, Z.H., Tao, Y.F., Li, R.H., Fang, F., Zhao, H., Li, G., Li, Y.H., Wang, J., Feng, X. and Pan, J. (2014) Histone acetyltransferase inhibitor II induces apoptosis in glioma cell lines via the p53 signaling pathway. Journal of Experimental & Clinical Cancer Research, 33, 1-15.
Yan, W., Liu, S. and Xu, E. (2013) Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8. Oncogene, 32, 599-609.
Yang, S., Yong, C., Yunqian, L., Xiaoyan, L., Jiayue, C., Ye, C., Tianyang, Z., Liyan, Z. and Gang, Z. (2019) Resveratrol suppresses epithelial-mesenchymal transition in GBM by regulating Smad-dependent signaling. Research article. BioMed Research International, 2019, 1-14.
Zeng, J., Sun, Y., Wu, K., Li, L., Zhang, G., Yang, Z., Wang, Z., Zhang, D., Xue, Y., Chen, Y., Zhu, G., Wang, X. and He, D. (2011) Chemopreventive and chemotherapeutic effects of intravesical silibinin against bladder cancer by acting on mitochondria. Molecular Cancer Therapeutics, 10, 104-116.
Zhang, Z., Zhang, G. and Kong, C. (2017) Targeted inhibition of Polo-like kinase 1 by a novel small-molecule inhibitor induces mitotic catastrophe and apoptosis in human bladder cancer cells. Journal of Cellular and Molecular Medicine, 21, 758-767.
Zheng, N., Liu, L., Liu, W., Li, F., Hayashi, T., Tashiro, S., Onodera, S. and Ikejima, T. (2017) Crosstalk of ROS/RNS and autophagy in silibinin-induced apoptosis of MCF-7 human breast cancer cells in vitro. Acta Pharmacologica Sinica, 38, 277-289.
Zhu, X.X., Ding, Y.H., Wu, Y., Qian, L.Y., Zou, H. and He, Q. (2016) Silibinin: a potential old drug for cancer therapy. Expert Review of Clinical Pharmacology, 9, 1323-1330.
معلومات مُعتمدة: CNPq-441836/2014-3 International Conselho Nacional de Desenvolvimento Científico e Tecnológico; CBB-APQ-01497-14 International Fundação de Amparo à Pesquisa do Estado de Minas Gerais; 23109.003267/2017-01 International Universidade Federal de Ouro Preto; 23109.003517/2018-85 International Universidade Federal de Ouro Preto
فهرسة مساهمة: Keywords: TP53 gene; cell cycle; gene expression; silibinin; urinary bladder cancer
المشرفين على المادة: 0 (Antineoplastic Agents, Phytogenic)
0 (Tumor Suppressor Protein p53)
4RKY41TBTF (Silybin)
تواريخ الأحداث: Date Created: 20200221 Date Completed: 20201029 Latest Revision: 20201029
رمز التحديث: 20240628
DOI: 10.1002/em.22363
PMID: 32078183
قاعدة البيانات: MEDLINE
الوصف
تدمد:1098-2280
DOI:10.1002/em.22363